Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 16 min ago
Peer-reviewedCC BY-NC-ND 4.0Future Cardiology

Physical activity and quality of life in patients with hypertrophic cardiomyopathy in Japan: a quantitative study

  • Hiroaki Kitaoka1
  • Toru Kubo1
  • Makio Torigoe2
  • Yuika Ikeda3
  • Kanako Shimoura4
  • Shintaro Suo4
  • Ryohei Takeda4
  • Yuichiro Maekawa5
5 affiliations
  1. 1Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, Japan
  2. 2Japan Medical, Bristol Myers Squibb K.K., Tokyo, Japan
  3. 3Health Economics and Outcomes Research, Bristol Myers Squibb K.K., Tokyo, Japan
  4. 4Patient Outcome Team, Medical Science and Writing Group, Mebix, Inc., Tokyo, Japan
  5. 5Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
Read full textPDFDOICite

Abstract

Aim: To describe the burden of hypertrophic cardiomyopathy (HCM) using patient-reported outcome tools and a study-specific questionnaire.

Patients and methods: This two-phase, cross-sectional, non-interventional, observational study (qualitative [previous] and quantitative [current]) included adults with HCM and New York Heart Association functional classification 2/3 recruited from healthcare facilities across Japan. The International Physical Activity Questionnaire (IPAQ), Kansas City Cardiomyopathy Questionnaire (KCCQ), Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ), and Hospital Anxiety and Depression Scale (HADS) were used alongside a questionnaire developed using the qualitative findings.

Results: The analysis included 120 patients (mean age, 59.1 ± 16.3 years; 55.5% [66/120] male), 60 each with non-obstructive and obstructive HCM. Patients with (vs. without) lifestyle changes had lower median IPAQ score (495.0 [363.0–1803.5] vs. 990.0 [369.4–2295.0], p = 0.159) and KCCQ – Clinical Summary Score (81.3 [65.6–90.7] vs. 92.0 [81.4–97.9], p < 0.001), and higher HADS-Depression (5.0 [3.0–8.0] vs. 2.0 [1.0–6.0], p = 0.001) and HCMSQ-shortness of breath (5.0 [2.0–6.0] vs. 3.0 [0.0–4.5], p < 0.001) scores. Most patients (83.9%) noticed HCM symptoms, and some patients attributed symptoms to causes other than HCM. Most patients (89.0%) told others about their HCM. Primary care physicians were the main information source (99.2%).

Conclusions: In this quantitative analysis, HCM affected patients’ lifestyles and physical activity.

Clinical trial registration: NCT06181617 (ClinicalTrials.gov).

Related

  1. Predictive Value of P-Wave Dispersion Combined with Left Atrial Reservoir Strain for Incident Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.
    Li Yu, Yan Zhang, Dandan Sun +2
    International journal of general medicinePeer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMCPMC
  2. Associations between physical activity expectations, health literacy, and life satisfaction in cancer patients: results of a quantitative cross-sectional study.
    Franziska Ostendorf, Emilia Hintze, Luise Schütze +7
    Journal of cancer research and clinical oncologyPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  3. Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
    Ya-Nan Shi, Jia-Jia Huang, Hong-Zhi Liu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossref
  4. Left Ventricular Diastolic Intraventricular Pressure Differences and Propagation Velocity with 4D-Flow MRI in Patients with Hypertrophic Cardiomyopathy
    L. V. Stipechi, D. Craiem, U. Gencer +5
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  5. Reclassification of Genetic Variants in Patients with Hypertrophic Cardiomyopathy from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
    S. Hespe, G. Powell, L. Catto +39
    medRxivPreprintCC BYFull textHuman geneticsmedRxiv

Cite

BibTeXRIS
BibTeX
@article{kitaoka2026physical,
  title = {{Physical activity and quality of life in patients with hypertrophic cardiomyopathy in Japan: a quantitative study}},
  author = {Hiroaki Kitaoka and Toru Kubo and Makio Torigoe and Yuika Ikeda and Kanako Shimoura and Shintaro Suo and Ryohei Takeda and Yuichiro Maekawa},
  journal = {Future Cardiology},
  year = {2026},
  month = oct,
  doi = {10.1080/14796678.2026.2745404},
  url = {https://doi.org/10.1080/14796678.2026.2745404},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Physical activity and quality of life in patients with hypertrophic cardiomyopathy in Japan: a quantitative study
AU  - Hiroaki Kitaoka
AU  - Toru Kubo
AU  - Makio Torigoe
AU  - Yuika Ikeda
AU  - Kanako Shimoura
AU  - Shintaro Suo
AU  - Ryohei Takeda
AU  - Yuichiro Maekawa
PY  - 2026
DA  - 2026/10/13
JO  - Future Cardiology
DO  - 10.1080/14796678.2026.2745404
UR  - https://doi.org/10.1080/14796678.2026.2745404
AB  - Aim: To describe the burden of hypertrophic cardiomyopathy (HCM) using patient-reported outcome tools and a study-specific questionnaire.  Patients and methods: This two-phase, cross-sectional, non-interventional, observational study (qualitative [previous] and quantitative [current]) included adults with HCM and New York Heart Association functional classification 2/3 recruited from healthcare facilities across Japan. The International Physical Activity Questionnaire (IPAQ), Kansas City Cardiomyopathy Questionnaire (KCCQ), Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ), and Hospital Anxiety and Depression Scale (HADS) were used alongside a questionnaire developed using the qualitative findings.  Results: The analysis included 120 patients (mean age, 59.1 ± 16.3 years; 55.5% [66/120] male), 60 each with non-obstructive and obstructive HCM. Patients with (vs. without) lifestyle changes had lower median IPAQ score (495.0 [363.0–1803.5] vs. 990.0 [369.4–2295.0], p = 0.159) and KCCQ – Clinical Summary Score (81.3 [65.6–90.7] vs. 92.0 [81.4–97.9], p < 0.001), and higher HADS-Depression (5.0 [3.0–8.0] vs. 2.0 [1.0–6.0], p = 0.001) and HCMSQ-shortness of breath (5.0 [2.0–6.0] vs. 3.0 [0.0–4.5], p < 0.001) scores. Most patients (83.9%) noticed HCM symptoms, and some patients attributed symptoms to causes other than HCM. Most patients (89.0%) told others about their HCM. Primary care physicians were the main information source (99.2%).  Conclusions: In this quantitative analysis, HCM affected patients’ lifestyles and physical activity.  Clinical trial registration: NCT06181617 (ClinicalTrials.gov).
SN  - 1479-6678
SN  - 1744-8298
ER  -